EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients

Guojun Yan, Kai Zhang, Lijun Yan, Yanbin Zhang

World Journal of Surgical Oncology · 2024

DOI: 10.1186/s12957-024-03426-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Guojun Yan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Yangfangdian Street, Haidian Dist…. Hauptthemen laut MEDLINE: Liver Neoplasms, Peritoneal Neoplasms, Cytoreduction Surgical Procedures, Hyperthermic Intraperitoneal Chemotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma with peritoneal metastasis (HCC-PM) has a poor outlook. Traditional treatments have limited effect on survival. The safety and efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) have been shown in other peritoneal cancers. This study evaluates the role of CRS + HIPEC in HCC-PM.

Methods

A retrospective analysis of HCC-PM patients treated with CRS + HIPEC at Beijing Shijitan Hospital from March 2017 to December 2023 was conducted, assessing clinical features, severe adverse events (SAEs), and overall survival (OS) rates.

Results

The study population comprised 10 HCC-PM patients who underwent CRS + HIPEC. The median peritoneal cancer index (PCI) was 25, and complete cytoreduction (CC0 ~ 1) was achieved in half of the patients. Three patients experienced SAEs within 30 days postoperatively. The 1-year, 3-year, and 5-year OS rates were recorded as 89.0%, 89.0%, and 21.0% respectively, with a median OS1 of 107.8 months and OS2 of 49.9 months. The median progression-free survival (PFS) was 5.0 months.

Conclusion

The application of CRS + HIPEC offers significant benefits to patients with HCC-PM. A selected group of patients may achieve prolonged PFS. Incorporating CRS + HIPEC into the treatment paradigm can thus be considered a strategic therapeutic option for patients with HCC-PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsPeritoneal NeoplasmsCytoreduction Surgical ProceduresHyperthermic Intraperitoneal ChemotherapyCarcinoma, HepatocellularHumansMaleFemaleRetrospective StudiesMiddle AgedSurvival RateCombined Modality TherapyPrognosisFollow-Up StudiesAdultAgedAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Cytoreductive surgeryHepatocellular carcinomaHyperthermic intraperitoneal chemotherapyPeritoneal metastasis

Autor:innen und Institutionen

  • Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Yangfangdian Street, Haidian District, Beijing, 100038, China.
  • Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, No. 10, Tieyi Road, Yangfangdian Street, Haidian District, Beijing, 100038, China. sjtyyzyb@mail.ccmu.edu.cn.

Zitieren

APA

Yan, G., Zhang, K., Yan, L., & Zhang, Y. (2024). Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03426-1

Vancouver

Yan G, Zhang K, Yan L, Zhang Y. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03426-1

BibTeX
@article{Yan2024,
  author = {Yan, Guojun and Zhang, Kai and Yan, Lijun and Zhang, Yanbin},
  title = {Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients},
  journal = {World Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1186/s12957-024-03426-1}
}
Kostenlos starten →